BioCryst Pharmaceuticals Inc (NAS:BCRX)
$ 7.82 -0.37 (-4.52%) Market Cap: 1.62 Bil Enterprise Value: 2.18 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 75/100

BioCryst Pharmaceuticals Inc at Wells Fargo Virtual Healthcare Conference Transcript

Sep 10, 2021 / 05:20PM GMT
Release Date Price: $15.2 (-0.33%)
Jacob William Hughes
Wells Fargo Securities, LLC, Research Division - Senior Analyst

Great. Thanks, everyone, for joining us. I am Jacob Hughes, Specialty Pharmaceuticals Analyst at Wells Fargo. Next up, we have BioCryst Pharmaceuticals. From the company, I'm very pleased to have President and CEO, Jon Stonehouse.

Investors can e-mail me questions via the platform, and I'll ask them on your behalf. Alternatively, you can e-mail me directly at [email protected].

Jon, I'll hand it over to you to give a little bit of an intro on your progress, and then maybe we can jump into Q&A from there.

Jon P. Stonehouse
BioCryst Pharmaceuticals, Inc. - CEO, President & Executive Director

Sure. Thanks, Jacob, and thanks for inviting us to your health care conference. Let me just make some real quick introductions of who's joining me. We've got Charlie Gayer, our Chief Commercial Officer; Helen Thackray, our Chief R&D Officer; John Bluth, our Chief Communications Officer; and Bill Sheridan, our Chief Medical Officer. And we're all

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot